Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML

Leukemia

Volumn 24, Issue 7, 2010, Pages 1375-1378

  Weisberg, E ^a   Deng, X ^b   Choi, H G ^b   Barrett, R ^a   Adamia, S ^a   Ray, A ^a   Moreno, D ^a   Kung, A L ^c   Gray, N ^b   Griffin, J D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; GNF 5; HG 78501; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; HG-7-85-01 COMPOUND; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; LETTER; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LEUKEMIA, EXPERIMENTAL; METABOLISM; PATHOLOGY; PRE B LYMPHOCYTE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; LEUKEMIA, EXPERIMENTAL; MICE; PIPERAZINES; PRECURSOR CELLS, B-LYMPHOID; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954656514     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.107     Document Type: Letter

References (8)

1. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-364.
2. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
3. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
5. Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S et al. Crystal structure of the T315I mutant of the Abl kinase. Chem Biol Drug Des 2007;70:171-181.
6. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Taebo S et al. Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases. Blood 2010 (Epub ahead of print).
7. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2:95-102.
8. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010;463:501-506.